Find Funding Opportunities

- This RFA is an initiative of the NIH Blueprint for Neuroscience Research (http://neuroscienceblueprint.nih.gov), a trans-NIH partnership to accelerate neuroscience research. Fifteen Institutes and Centers are participating in the Neuroscience Blueprint. This RFA will be administered by the National Institute on Drug Abuse (NIDA) on behalf of the Neuroscience Blueprint. - This funding opportunity will support integrated research education and research training programs that provide interdisciplinary training in basic neuroscience and the theoretical and technological approaches of computational neuroscience.

The goals of NIH-supported research training and career development programs are to help ensure that diverse pools of highly trained scientists are available in adequate numbers and in appropriate research areas to address the Nation s biomedical, behavioral, and clinical research needs.NIH mentored career development awards provide mentored research experiences to gain additional expertise in a new research area or in an area that will significantly enhance an investigator s research capabilities. It is expected that the mentored research and career development experience will lead to an independent and productive research career.

The National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases solicit applications for translational research projects in muscular dystrophy. Several emerging pathways to treatment of muscular dystrophy show promise, ranging from palliative therapies that can markedly delay onset or progression of the disease to genetic or stem cell approaches that may reverse or eliminate the condition. The objective of this initiative is to encourage the pursuit of a broad range of translational research strategies for therapeutic development in muscular dystrophy.

The National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases solicit applications for translational research projects in muscular dystrophy. Several emerging pathways to treatment of muscular dystrophy show promise, ranging from palliative therapies that can markedly delay onset or progression of the disease to genetic or stem cell approaches that may reverse or eliminate the condition. The objective of this initiative is to encourage the pursuit of a broad range of translational research strategies for therapeutic development in muscular dystrophy.

This RFA is an initiative of the NIH Blueprint for Neuroscience Research (http://neuroscienceblueprint.nih.gov), a trans-NIH partnership to accelerate neuroscience research. Fifteen Institutes and Centers are participating in the Neuroscience Blueprint. This RFA will be administered by the NIMH on behalf of the Neuroscience Blueprint. This funding opportunity supports the design, creation, and characterization of recombinase-expressing C57BL/6 mouse lines to aid in studies of nervous system development and/or function. These so-called “driver lines” should specify expression in distinct cell types and/or other useful temporospatial expression patterns in the nervous system. Drivers with the greatest utility (such as inducibility) and relevance to neuroscience research will be given priority. Applicants should have the capability to create and validate a minimum of 10 novel driver lines in the funding period specified.

Support for advanced training in collaborative, multidisciplinary, international clinical, operational, health services and prevention science research on non-communicable disorders and diseases for health researchers from low- and middle-income countries.

- This RFA is an initiative of the NIH Blueprint for Neuroscience Research (http://neuroscienceblueprint.nih.gov), a trans-NIH partnership to accelerate neuroscience research. Fifteen Institutes and Centers are participating in the Neuroscience Blueprint. This RFA will be administered by the NIMH on behalf of the Neuroscience Blueprint. - This funding opportunity supports the development and initiation or the significant expansion of courses on the neurobiology of disease for graduate students receiving basic neuroscience training. It is expected that each course will span a breadth of diseases and disorders affecting the nervous system, emphasizing links and common themes across diseases/disorders, and addressing both the pathology of these diseases/disorders and their basic science underpinnings.

- This RFA is an initiative of the NIH Blueprint for Neuroscience Research (http://neuroscienceblueprint.nih.gov), a trans-NIH partnership to accelerate neuroscience research. Fifteen Institutes and Centers are participating in the Neuroscience Blueprint. This RFA will be administered by NIDA on behalf of the Neuroscience Blueprint. - The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible institutions to support research trainees in translational neurobiology of disease. Four types of full-time trainees may be supported: 1) Predoctoral Trainees in a neuroscience-oriented PhD or equivalent doctoral degree program; 2) Trainees in an accredited MD/PhD program at a medical school who will receive both an MD, DO, DDS, or equivalent professional degree and a PhD; 3) Short-Term Research Training for Health-Professional Students; and 4) Postdoctoral Trainees with research or clinical doctoral degrees to prepare for a research career in translational neuroscience. - Applicant institutions may tailor their proposed program with a mix of trainee types with various levels of research experience. However, training programs are strongly encouraged to include concurrent training of both basic and clinical researchers. The proposed training programs must be thematic, focusing not upon a specific disease but upon mechanisms that may be shared by a number of diseases and disorders and must include training in the progression of disease from molecules to behavior, to prevention or treatment.

This Program Announcement with review (PAR) invites applications for the Morris K. Udall Parkinsons Disease Centers of Excellence Program.

This funding opportunity announcement (FOA) from the National Cancer Institute (NCI), the National Institute of Environmental Health Sciences (NIEHS), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the National Institute of Neurological Disorders and Stroke (NINDS) invites Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) for the development and delivery of novel in vivo image acquisition or enhancement technologies and methods for biomedical imaging and image-guided interventions and therapy (applications may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies).